Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trafermin - Nobelpharma

Next Previous
Search
Drug Profile

Trafermin - Nobelpharma

Alternative Names: NPC 18; Retympa

Latest Information Update: 10 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nobelpharma
  • Developer Harvard University; Kaken Pharmaceutical; Massachusetts Eye and Ear; Nobelpharma
  • Class Fibroblast growth factors; Peptide fragments; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Tympanic membrane perforation
  • Discontinued Hearing disorders

Most Recent Events

  • 07 Feb 2025 Nobelpharma expects approval of Trafermin for Tympanic membrane perforation in December 2026 (Nobelpharma pipeline, February 2025)
  • 10 Sep 2024 Discontinued - Phase-III for Hearing disorders in Japan (unspecified route)
  • 20 Jul 2023 Nobel pharma expects approval for Hearing-disorders in March 2026 (Nobelpharma pipeline, July 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top